Tag Archive > Human Health Care

Eisai registriert ersten Produkte in Südafrika

Hatfield, England (ots/PRNewswire) – Expansionspläne in Afrika mit der Einreichung von zwei Produkten Eisai kündigt den Ausbau seiner Geschäftstätigkeit in Südafrika an und hat die beiden Arzneimittel Halaven(R) (Eribulin) – für die Behandlung von metastasiertem Brustkrebs – und Fycompa(R) (Perampanel) – zur Behandlung von Epilepsie – zur Zulassung bei der südafrikanischen Gesundheitsbehörde (The Medicines Control […]

Continue reading

, , , , , , , , , , , , ,

Eisai Expands in Israeli Market With Approval of Halaven

Hatfield, England (ots/PRNewswire) – Metastatic breast cancer treatment Halaven(R) (eribulin) provides a statistically significant overall survival benefit for women with the disease Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from the […]

Continue reading

, , , , , , , , ,

Once-Daily Epilepsy Treatment now Available in Sweden

Hatfield, England (ots/PRNewswire) – ? Reimbursement granted for Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited today announces the launch of Zebinix(R) (eslicarbazepine acetate) which will receive full reimbursement from the Swedish health authorities. Once-daily Zebinix is indicated as an adjunctive (add-on) therapy for adults with partial-onset seizures, with […]

Continue reading

, , , , , ,

Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting

Hatfield, England (ots/PRNewswire) – Eisai announced today that 12 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, from 1-5 June 2012. These studies highlight Eisai’s current product portfolio and oncology pipeline, reinforcing the company’s commitment to patients […]

Continue reading

, , , , , , , , ,

Ergebnisse der zulassungsstudie zu Eisais in klinischer prüfung befindlichem antiepileptikum perampanel IN Neurology® Veröffentlicht

Hatfield, England (ots/PRNewswire) – – Diese Pressemitteilung ist nur für europäische Medien bestimmt Eisai gab heute die Veröffentlichung der Ergebnisse einer Phase-III-Zulassungsstudie[ 1] zu Perampanel, einem hochselektiven, nicht-kompetitiven AMPA-Glutamatrezeptor-Antagonisten, der sich in der klinischen Testphase befindet, bekannt. Die Substanz wurde als Zusatzmedikament zur Behandlung von fokalen Anfällen bei Patienten mit Epilepsie entwickelt. Die heute in […]

Continue reading

, , , , , , , , ,

Novel Once-Daily Epilepsy Treatment now Available in France

Hatfield, England (ots/PRNewswire) – Reimbursement granted for Zebinix(R) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited announces the launch of Zebinix(R) (eslicarbazepine acetate) in France. Upon launch, this novel epilepsy drug will receive full reimbursements from the French health authorities. Once-daily eslicarbazepine acetate is indicated as an adjunctive (add-on) therapy for adults […]

Continue reading

, , , , , ,

Eisai Opens Representative Office in Dubai

Hatfield, England (ots/PRNewswire) – New EMEA Dubai Office Part of Expansion Plans into Middle East and Parts of Africa PRESS RELEASE NOT INTENDED FOR DUBAI MEDIA Japanese company Eisai is expanding its geographical and patient reach by opening a new regional representative office in Dubai today. The Eisai EMEA (Europe, Middle East and Africa) Dubai […]

Continue reading

, , , , , , , ,

Eisai oncology stellt auf der asco-jahrestagung neue forschungs­arbeiten zu produktportfolio und -pipeline vor

Hatfield, Grossbritannien (ots/PRNewswire) – Eisai hat heute die Präsentation von zehn Abstracts auf der 47. Jahrestagung der American Society of Clinical Oncology (ASCO) angekündigt, die vom 3. bis 7. Juni 2011 in Chicago stattfindet. Darin werden die Ergebnisse neuer Studien zu Schilddrüsen- und metastasiertem Brustkrebs, Ovarialkarzinom und anderen Krebsarten vorgestellt. Die Studien geben einen Einblick […]

Continue reading

, , , , , , , ,

Zebinix(R) Now Available in Greece

Hatfield, England (ots/PRNewswire) – Zebinix(R) (eslicarbazepine acetate), an add-on (adjunctive) therapy for adults with partial-onset seizures, with or without secondary generalisation (where the seizure extensively affects consciousness of the patients by propagation to both sides of the brain), has recently been launched in Greece by Arriani Pharmaceuticals, Eisai’s chosen partner in Greece. In April 2009, […]

Continue reading

, , , , , , , , , ,

Eisai Opens for Business in the Netherlands

Hatfield, England (ots/PRNewswire) – Eisai Europe Limited, a subsidiary of Eisai Co., Ltd announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam. The first Eisai product on the Dutch market is the epilepsy treatment Zonegran (zonisamide). Commenting on the opening of the new subsidiary, […]

Continue reading

, , , , , , , ,

Eisai Opens GBP100 Million European Headquarters Facility in the UK

Hatfield, England (ots/PRNewswire) – – Leading Research-Based Pharmaceutical Company Creates New Manufacturing and Research Jobs in UK Eisai, one of the world’s leading pharmaceutical companies, today officially opened its new ‘European Knowledge Centre’ (the EKC) in Hatfield, Hertfordshire. Committed to developing new medicines for patients with conditions such as Alzheimer’s disease, Parkinson’s disease and epilepsy, […]

Continue reading

, , ,